[倍他司汀在耳蜗-前庭疾病患者中的应用]
[The use of betaserk in patients with cochlear-vestibular disorders].
作者信息
Kadymov M I, Poliakova T S, Vladimirova T N
出版信息
Vestn Otorinolaringol. 1998(5):49-50.
PMID:9793432
Abstract
20-year experience with 220 cases of cochleovestibular disorders treated with betaserk shows high efficacy of this drug in the above patients, especially at initial stages of Meniere's disease. Betaserk is recommended for wide outpatient practice.
摘要
对220例耳蜗前庭疾病患者使用倍他司汀进行治疗的20年经验表明，该药物对上述患者具有较高疗效，尤其是在梅尼埃病的初始阶段。建议在广泛的门诊实践中使用倍他司汀。
相似文献
1
[The use of betaserk in patients with cochlear-vestibular disorders].
Vestn Otorinolaringol. 1998(5):49-50.
2
[Betaserk efficiency in cochlear and vestibular disorders in the regional surdocenter].
Vestn Otorinolaringol. 2001(3):61.
3
[Betaserk in therapy of cochleovestibular disordes].
Vestn Otorinolaringol. 2006(4):59-60.
4
[The role of betaserk in combined treatment of neurosensory hypoacusis and vestibulopathy in childhood].
Vestn Otorinolaringol. 2004(2):9-12.
5
[Vestibo in the treatment of cochleovestibular disorders].
Vestn Otorinolaringol. 2008(6):52-4.
6
7
[Trimetazidine versus betahistine in vestibular vertigo. A double blind study].
Ann Otolaryngol Chir Cervicofac. 1990;107 Suppl 1:11-9.
8
[Vestibular disorders in patients with otosclerosis: prevalence, diagnostic and therapeutic options].
Vestn Otorinolaringol. 2009(2):20-2.
9
[Use of monotreane in the treatment of patients with cochleovestibular disorders].
Vestn Otorinolaringol. 1989 Sep-Oct(5):20-2.
10
Report from a Consensus Conference on the treatment of Ménière's disease with betahistine: rationale, methodology and results.
Acta Otorhinolaryngol Ital. 2018 Oct;38(5):460-467. doi: 10.14639/0392-100X-2035.
Zotero 插件